Teriparatide Treatment in Patients withWNT1orPLS3Mutation-Related Early-Onset Osteoporosis - A Pilot Study | Zendy

VilleValtteri Välimäki | Zendy; Outi Mäkitie | Zendy; Renata C. Pereira | Zendy; Christine Lainé | Zendy; Katherine WesselingPerry | Zendy; Jorma A. Määttä | Zendy; Mikko Kirjavainen | Zendy; Heli Viljakainen | Zendy; Matti Välimäki | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Teriparatide Treatment in Patients withWNT1orPLS3Mutation-Related Early-Onset Osteoporosis - A Pilot Study

Author(s) -

VilleValtteri Välimäki,

Outi Mäkitie,

Renata C. Pereira,

Christine Lainé,

Katherine WesselingPerry,

Jorma A. Määttä,

Mikko Kirjavainen,

Heli Viljakainen,

Matti Välimäki

Publication year - 2016

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2016-2423

Subject(s) - medicine , teriparatide , osteoporosis , bone remodeling , endocrinology , n terminal telopeptide , bone mineral , femoral neck , urology , osteocalcin , chemistry , alkaline phosphatase , biochemistry , enzyme

We previously identified 2 Finnish families with dominantly inherited, low-turnover osteoporosis caused by mutations in WNT1 or PLS3.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Address

About

Learn

Download the Zendy App

Discover

Explore